P461: COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysisECCO'22Year: 2022
Authors: Kokkotis, G.(1);Kitsou, K.(2);Xynogalas, I.(3);Spoulou, V.(2);Magiorkinis, G.(4);Poulakou, G.(3);Syrigos, K.(3);Bamias, G.(1);
(1)3rd Department of Internal Medicine- National and Kapodistrian University of Athens- Sotiria Hospital, GI Unit, Athens, Greece;(2)First Department of Paediatrics- National and Kapodistrian University of Athens, Immunobiology and Vaccinology Research Lab IVRL, Athens, Greece;(3)National and Kapodistrian University of Athens- Sotiria Hospital, 3rd Department of Internal Medicine, Athens, Greece;(4)National and Kapodistrian University of Athens- School of Medicine, Department of Hygiene- Epidemiology and Medical Statistics, Athens, Greece;
P462: Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of responseECCO'22Year: 2022
Authors: Srinivasan, A.(1,2,3);De Cruz, P.(3,4);Sam, M.(5,6,7);Toong, C.(5,6,7,8);van Langenberg, D.(1,2);
(1)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(2)Monash University, Eastern Health Clinical School, Melbourne, Australia;(3)Austin Health, Department of Gastroenterology, Melbourne, Australia;(4)University of Melbourne, Austin Academic Centre, Melbourne, Australia;(5)NSW Health Pathology Liverpool Hospital, Department of Immunopathology, Sydney, Australia;(6)Ingham Institute of Applied Sciences, Immunology Research Group, Sydney, Australia;(7)University of NSW, South Western Sydney Clinical School, Sydney, Australia;(8)Liverpool Hospital, Department of Immunology, Sydney, Australia;
P463: Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity markerECCO'22Year: 2022
Authors: Jójárt, B.(1);Molnár, T.(2);Kata, D.(3);Szabó, V.(1);Varga, Á.(1);Resál, T.(4);Bacsúr, P.(4);Szántó, K.(4);Földesi, I.(3);Molnár, T.(4);Maléth, J.(1);Farkas, K.(4);
(1)University of Szeged, Szent-Györgyi Albert Medical School- Department of Medicine- Szeged- Hungary- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group- Szeged- Hungary- HCEMM-USz Molecular Gastroenterology Research Group- Szeged- Hungary, Szeged, Hungary;(2)University of Szeged, Szent-Györgyi Albert Medical School- Department of Medicine- Szeged- Hungary- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group- Szeged- Hungary, Szeged, Hungary;(3)University of Szeged, Szent-Györgyi Albert Medical School- Institute of Laboratory Medicine- Szeged- Hungary, Szeged, Hungary;(4)University of Szeged, Szent-Györgyi Albert Medical School- Department of Medicine- Szeged- Hungary, Szeged, Hungary;University of Szeged Szent-Györgyi Albert Medical School Department of Medicine HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group
P464: Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?ECCO'22Year: 2022
Authors: DebenMSc, D.(1);Creemers, R.(2,3);Van Adrichem, A.(4);Drent, R.(5);Merry, A.(6);Leers, M.(5);Van Bodegraven, A.(2,7);Wong, D.(1);
(1)Zuyderland MC, Dept. of Clinical Pharmacy- Clinical pharmacology and Toxicology, Sittard-Geleen, The Netherlands;(2)Zuyderland MC, Dept. of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen, The Netherlands;(3)Maastricht University Medical Center, Dev. of Gastroenterology and Hepatology, Maastricht, The Netherlands;(4)Bravis MC, Dept. of Clinical Chemistry and Haematology, Roosendaal, The Netherlands;(5)Zuyderland MC, Dept. Of Clinical Chemistry and Haematology, Sittard-Geleen, The Netherlands;(6)Zuyderland MC, Zuyderland Academy, Sittard-Geleen, The Netherlands;(7)Amsterdam University Medical Center, Dept. of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P465: Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?ECCO'22Year: 2022
Authors: Fumery, M.(1);Nancey, S.(2);Filippi, J.(3);Altwegg, R.(4);Hebuterne, X.(3);Boschetti, G.(2);Veyrard , P.(5);Yzet, C.(1);Paul, S.(6);Roblin, X.(5);
(1)Amiens University Hospital, Gastroenterology, Amiens Cedex 1, France;(2)Lyon University Hospital, Gastroenterology, Lyon, France;(3)Nice University Hospital, Gastroenterology, Nice, France;(4)Montpellier University Hospital, Gastroenterology, Montpellier, France;(5)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(6)Saint Etienne University Hospital, Immunology, Saint Etienne, France;GOLILOR Study group
P466: Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in JapanECCO'22Year: 2022
Authors: Nakamura, S.(1);Asano, T.(2);Tanaka, Y.(3);Sugimoto, K.(4);Yoshigoe, S.(5);Suzuki, Y.(6);
(1)Osaka Medical and Pharmaceutical University, Second Department of Internal Medicine, Osaka, Japan;(2)Janssen Pharmaceutical K.K., Medical Science Liaison Department, Tokyo, Japan;(3)Janssen Pharmaceutical K.K., Statistics & Decision Sciences Department, Tokyo, Japan;(4)Janssen Pharmaceutical K.K., Safety Risk Management Department, Tokyo, Japan;(5)Janssen Pharmaceutical K.K., Immunology- Infectious Diseases & Vaccine Department, Tokyo, Japan;(6)Ginza Central Clinic, Gastroenterology, Tokyo, Japan;
P467: Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practiceECCO'22Year: 2022
Authors: Bjørlykke, K.(1);Jahnsen, J.(1);Brynskov, J.(2);Molander, P.(3);Eberhardson, M.(4);Davidsdottir, L.G.(5);Sipponen, T.(3);Hjortswang, H.(4);Langholz, E.(2);Jørgensen, K.K.(1);Steenholdt, C.(2);
(1)Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway;(2)Herlev Hospital, Department of Gastroenterology, Herlev, Denmark;(3)Helsinki University Hospital, Abdominal Center- Gastroenterology, Helsinki, Finland;(4)Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden;(5)Landspítali- The National University Hospital of Iceland, Department of Gastroenterology, Reykjavik, Iceland;
P468: Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North studyECCO'22Year: 2022
Authors: Floden, L.(1);Pham, T.P.(2);Kumar, J.(3);Becker, B.(3);Shaw, J.W.(3);Tencer, T.(3);
(1)Clinical Outcomes Solutions, Biostatistics, Chicago, United States;(2)Clinical Outcomes Solutions, Research, Chicago, United States;(3)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;
P469: Infliximab for induction of medically-induced remission in Crohn's disease: a Cochrane systematic reviewECCO'22Year: 2022
Authors: Radford, S.(1);Sinopoulou, V.(2);Gordon, M.(2);Eldragini, M.E.A.A.(1);Darie, A.M.(1);Akobeng, A.(3);Moran, G.W.(1);
(1)Nottingham University Hospitals NHS Trust, NIHR Nottingham Biomedical Research Centre - Gastrointestinal and Liver disorders theme, Nottingham, United Kingdom;(2)UCLan, School of Medicine, Preston, United Kingdom;(3)Sidra Medicine, Medicine, Doha, Qatar;
P470: Real-world characteristics and complications of patients with Ulcerative Colitis receiving conventional therapy in the public healthcare system in BrazilECCO'22Year: 2022
Authors: Galhardi Gasparini, R.(1);Yukie Sassaki, L.(2);Lima Martins, A.(3);Saad Hossne, R.(4);Watanabe de Oliveira, R.(5);Yang Santos, C.(6);Biatti Barreto, T.(7);
(1)SETE – Specialized Medical Center, Gastroenterology Department, Marília - SP, Brazil;(2)Sao Paulo State University - UNESP- Medical School, Gastroenterology Department, Botucatu - SP, Brazil;(3)Espirito Santos Federal University - UFES, Gastroenterology Department, Vitoria - ES, Brazil;(4)Sao Paulo State University - UNESP- Medical School, Surgery Department, Botucatu - SP, Brazil;(5)IQVIA, Real-World Insights, Sao Paulo - SP, Brazil;(6)Takeda Pharmaceuticals, Clinical Research, Sao Paulo - SP, Brazil;(7)Takeda Pharmaceuticals, Medical Affairs, Sao Paulo - SP, Brazil;
P472: Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysisECCO'22Year: 2022
Authors: Le Cosquer, G.(1);Capirchio, L.(2);Rivière, P.(1);de Suray, N.(2);Poullenot, F.(1);De Vroey, B.(2);Berger, A.(1);Denis, M.A.(2);Zerbib, F.(1);Bachmann, R.(3);Remue, C.(3);Celerier, B.(4);Leonard, D.(3);Denost, Q.(4);Kartheuser, A.(3);Laharie, D.(1);Dewit, O.(2);
(1)Centre Hospitalo-Universitaire of Bordeaux- Hôpital Haut-Lévêque – University of Bordeaux, Hepato-gastroenterology and digestive oncology, Bordeaux, France;(2)Cliniques Universitaires Saint-Luc – Catholic University of Louvain, Hepato-gastroenterology, Brussels, Belgium;(3)Cliniques Universitaires Saint-Luc – Catholic University of Louvain, Colorectal surgery, Brussels, Belgium;(4)Centre Hospitalo-Universitaire of Bordeaux- Hôpital Haut-Lévêque – University of Bordeaux, Digestive and endocrine surgery, Bordeaux, France;
P473: Real world experience with the Crohn's Disease Exclusion Diet (CDED) in a tertiary IBD clinicECCO'22Year: 2022
Authors: Fliss Isakov, N.(1);Anbar, R.(2);Cooperstein, A.(2);Helbert, G.(2);Hirsch, A.(1);Ron, Y.(1);Thurm, T.(1);Maharshak, N.(1);
(1)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases- Sackler Faculty of Medicine, Tel Aviv, Israel;(2)Tel Aviv Sourasky Medical Center, Nutrition and dietetics department, Tel Aviv, Israel;
P474: Prevalence of fecal incontinence and clinical characteristics of IBD patients in remission and treated with biologics – experience from a tertiary referral centerECCO'22Year: 2022
Authors: Jelakovic, M.(1);Turk, N.(1);Brinar, M.(1);Barisic, A.(1);Grgic, D.(1);Cukovic-Cavka, S.(1);Krznaric, Z.(1);
(1)KBC Zagreb, Department of Gastroenterology and Hepatology, Zagreb, Croatia;
P475: Profiling the use of Complementary Alternative Medicines among IBD patientsECCO'22Year: 2022
Authors: Sudhakar, P.(1);Stiers, R.(1);Dycker, E.D.(2);Geens, P.(2);Paps, A.(2);Lambrechts, T.(2);Keersmaekers, B.(2);Sabino, J.(1,3);Ferrante, M.(1,3);Vermeire, S.(1,3);Verstockt, B.(1,3);
(1)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium;(2)University Hospital Leuven, IBD Leuven, Leuven, Belgium;(3)University Hospital Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P477: Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE OpenECCO'22Year: 2022
Authors: Allegretti, J.R.(1);Gecse, K.B.(2);Chiorean, M.V.(3);Argollo, M.(4);Guo, X.(5);Lawendy, N.(5);Su, C.(5);Mundayat, R.(6);Paulissen, J.(6);Salese, L.(5);Irving, P.M.(7);
(1)Brigham and Women's Hospital, Division of Gastroenterology- Hepatology and Endoscopy, Boston- MA, United States;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)-, Swedish Medical Center, Seattle- WA, United States;(4)Federal University of São Paulo, Department of Gastroenterology, São Paulo, Brazil;(5)-, Pfizer Inc, Collegeville- PA, United States;(6)-, Pfizer Inc, New York- NY, United States;(7)Guy’s and St Thomas’ Hospital, IBD Unit, London, United Kingdom;
P478: The role of proactive measurement of adalimumab trough levels and antibodies to adalimumab in Greek patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Orfanoudaki, E.(1);Gazouli, M.(2);Theodoraki, E.(1);Foteinogiannopoulou, K.(1);Andreou, N.P.(2);Koutroubakis, I.E.(1);
(1)University Hospital of Heraklion- Medical School- University of Crete, Gastroenterology, Heraklion Crete, Greece;(2)Medical School- National and Kapodistrian University of Athens- Greece, Department of Basic Medical Sciences- Laboratory of Biology, Athens, Greece;
P480: Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitisECCO'22Year: 2022
Authors: Zelnik Yovel, D.(1);Meyer, S.(2);Richter, V.(1);Shirin, H.(1);Broide, E.(1);
(1)Shamir Medical center, Gastroenterology, Zerifin, Israel;(2)Ariel University, Faculty of Health Sciences, Ariel, Israel;
